1 Original research

| 2 | Associations of COVID-19 Symptoms with Omicron Subvariants BA.2 and BA.5, Host Status, |
|----|---|
| 3 | and Clinical Outcomes: A Registry-Based Observational Study in Sapporo, Japan |
| 4 | |
| 5 | Sho Nakakubo ¹ * [#] , M.D., Ph.D.; Naoki Kishida ² *, M.D., Ph.D.; Kenichi Okuda ³ *, M.D., Ph.D.; |
| 6 | Keisuke Kamada ^{1,4,5} , M.D., Ph.D.; Masami Iwama ⁶ ; Masaru Suzuki ¹ , M.D., Ph.D.; Isao Yokota ⁷ , |
| 7 | Ph.D.; Yoichi M. Ito ⁸ , Ph.D.; Yasuyuki Nasuhara ⁹ , M.D., Ph.D.; Richard C. Boucher ³ , M.D.; Satoshi |
| 8 | Konno ^{1,10} , M.D., Ph.D. |
| 9 | ¹ Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan |
| 10 | ² Emergency Management Bureau, City of Sapporo, Sapporo, Japan |
| 11 | ³ Marsico Lung Institute/Cystic Fibrosis Research Center, University of North Carolina at Chapel |
| 12 | Hill, Chapel Hill, NC, United States |
| 13 | ⁴ Department of Mycobacterium Reference and Research, The Research Institute of Tuberculosis, |
| 14 | Japan Anti-Tuberculosis Association, Tokyo, Japan |
| 15 | ⁵ Department of Epidemiology and Clinical Research, The Research Institute of Tuberculosis, Japan |
| 16 | Anti-Tuberculosis Association, Tokyo, Japan |
| 17 | ⁶ Management Section, Medical Management Office, Health and Welfare Bureau, City of Sapporo, |
| 18 | Sapporo, Japan |
| 19 | ⁷ Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Sapporo, Japan |

- ⁸ Data Science Center, Promotion Unit, Institute of Health Science Innovation for Medical Care,
- 21 Hokkaido University Hospital, Sapporo, Japan
- ⁹ Division of Hospital Safety Management, Hokkaido University Hospital, Sapporo, Japan
- ¹⁰ Hokkaido University, Institute for Vaccine Research and Development
- 24 (*These authors equally contributed to the work)
- 25
- ²⁶ [#]Corresponding author:
- 27 Sho Nakakubo, MD, PhD
- 28 Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University
- 29 North 15 West 7, Kita-ku, Sapporo 060-8638, Japan
- 30 E-mail: shonakakubo@pop.med.hokudai.ac.jp
- 31 Tel: +81-11-706-5911
- 32
- 33

34 Abstract

| 35 | Background: Previous SARS-CoV-2 infection and vaccination, coupled to rapid evolution of |
|----|---|
| 36 | SARS-CoV-2 variants, have modified COVID-19 clinical manifestations. We characterized clinical |
| 37 | symptoms of COVID-19 individuals in omicron BA.2 and BA.5 Japanese pandemic periods to |
| 38 | identify omicron and subvariant associations between symptoms, immune status, and clinical |
| 39 | outcomes. |
| 40 | Methods: Individuals registered in Sapporo's web-based COVID-19 information system entered 12 |
| 41 | pre-selected symptoms, days since symptom onset, vaccination history, SARS-CoV-2 infection |
| 42 | history, and background. Symptom frequencies, variables associated with symptoms, and symptoms |
| 43 | associated with progression to severe disease were analysed. |
| 44 | Results: For all omicron-infected individuals, cough was the most common symptom (62.7%), |
| 45 | followed by sore throat (60.7%), nasal discharge (44.3%), and fever (38.8%). Omicron BA.5 |
| 46 | infection was associated with a higher symptom burden than BA.2 in vaccinated and unvaccinated |
| 47 | individuals. Omicron breakthrough-infected individuals with \geq 3 vaccinations or previous infection |
| 48 | were less likely to exhibit systemic symptoms, but more likely to exhibit upper respiratory symptoms. |
| 49 | Infected elderly individuals had lower odds for all symptoms, but, when symptoms were manifest, |
| 50 | systemic symptoms were associated with an increased risk, whereas upper respiratory symptoms |
| 51 | with a decreased risk, of severe disease. |

52 Conclusion: Host immunological status, omicron subvariant, and age were associated with a

| 53 | spectrum of COVID-19 symptoms and outcomes. BA.5 produced a greater symptom burden than |
|----|--|
| 54 | BA.2. Vaccination and prior infection mitigated systemic symptoms and improved outcomes, but |
| 55 | increased upper respiratory tract symptom burden. Systemic, but not upper respiratory, symptoms in |
| 56 | the elderly heralded severe disease. |
| 57 | |
| 58 | Keywords: COVID-19, Omicron subvariant, vaccination, upper respiratory symptoms, older age. |
| 59 | |
| 60 | |

61 Introduction

| 62 | The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory |
|----|--|
| 63 | syndrome 2 (SARS-CoV-2), has caused more than 657 million infections worldwide ¹ . Since early in |
| 64 | the pandemic, multifaceted host factors, e.g., age and underlying disease, have been reported to |
| 65 | impact the clinical course of individuals infected with SARS-CoV-2 ²⁻⁵ . Associated with the |
| 66 | widespread implementation of SARS-CoV-2 vaccines and previous infections, the severity and |
| 67 | mortality rates of the COVID-19 syndrome have decreased ⁵⁻⁷ . The emergence of mutant strains may |
| 68 | have also modified the clinical manifestations of COVID-19 ^{8,9} . A challenge for healthcare |
| 69 | providers/public health officials is appropriately advising individuals with breakthrough infections |
| 70 | and implementing healthcare strategies in the current omicron pandemic period ¹⁰⁻¹² . |

Patient clinical symptoms are the most accessible information describing the state of 71 72 individuals with infections in healthcare settings. However, data linking patient manifestations to 73viral, host factor, and clinical outcomes must be continuously updated to maximize their utility and guide appropriate healthcare strategies^{13,14}. Studies designed to compare the symptoms of alpha vs. 74 delta SARS-CoV-2 variants with those of the original Wuhan strain¹⁵, and the original omicron 75 variant compared to the delta variant, helped guide healthcare strategies⁸. However, no large-scale 76 77 epidemiological studies describing COVID-19 symptoms and outcomes as a function of host factors across newer omicron subvariants are available. 78

79

Sapporo, a Japanese metropolitan city with 2 million people, launched a registration system

| 80 | to automate the acquisition of self-entered personal information from individuals with COVID-19. |
|----|---|
| 81 | This unique system, in which individuals enter their current status via the internet, enables the |
| 82 | collection of timely data describing COVID-19 symptoms that can be linked to databases |
| 83 | representing individuals' backgrounds, vaccination and previous SARS-CoV-2 infection status, and |
| 84 | severity outcomes. Our objective was to update the characterization of COVID-19 clinical symptoms |
| 85 | during the omicron BA.2-BA.5 variant pandemic period and identify associations between clinical |
| 86 | symptoms, host factors, immune status, and clinical outcomes relevant to the patient and healthcare |
| 87 | communities. |
| 88 | |
| 89 | Methods |
| 90 | Study population and data sources |
| 91 | This registry-based observational study was based on the Sapporo population. Data from |
| 92 | treatment decision sites (TDS) and registration centres for test-positive patients (RCPP) were utilized |
| 93 | for analyses (Fig. S1). The TDS is a system launched by the City of Sapporo to notify individuals |
| 94 | with a COVID-19 diagnosis of the need for hospitalization and clinical advice. Individuals eligible |
| 95 | for enrolment in the TDS were: 1) symptomatic individuals who visited a medical institution and |
| 96 | tested positive for SARS-CoV-2 (polymerase chain reaction or antigen test), and 2) individuals who |
| 97 | were not tested for SARS-CoV-2 but developed new symptoms after a household member tested |
| 98 | positive for SARS-CoV-2. Those diagnosed with COVID-19 were requested to immediately register |

| 99 | clinical information with the TDS through a web device, including the onset of any newly developed |
|-----|--|
| 100 | symptoms and the presence/absence of 12 preselected specific symptoms. The RCPP is a registration |
| 101 | system operated by the City of Sapporo for symptomatic individuals who cannot visit a healthcare |
| 102 | provider. The RCPP sends SARS-CoV-2 antigen test kits to symptomatic individuals at home upon |
| 103 | request. A self-test is conducted, and information identical to that for the TDS is entered into the |
| 104 | RCPP system by test-positive individuals. Data from both systems are integrated and stored at the |
| 105 | Sapporo City Public Health Center. Because both systems share identification information assigned |
| 106 | to individuals with COVID-19, case duplication is not possible. Data describing previous |
| 107 | SARS-CoV-2 infection and progression to severe disease are collected from the Health Center |
| 108 | Real-time Information-sharing System on COVID-19 operated by the Ministry of Health, Labor, and |
| 109 | Welfare, as well as data linked to patient information in the TDS and RCPP. Vaccination history, |
| 110 | including the timeline of vaccination, was accessed from the Vaccination Record System operated by |
| 111 | the Japan Government Digital Agency (Fig. S1). |
| 112 | Individuals were excluded from the study if they: (1) entered the date of onset |
| 113 | inappropriately, (2) were registered > 5 days after symptom onset, or (3) were asymptomatic. |
| 114 | Detailed inclusion and exclusion criteria and the treatment of missing values are described in |

115 Supplementary methods.

116

117 Data collected

| 118 | The following data were extracted from the TDS and RCPP: 1) date of first symptom onset; |
|-----|---|
| 119 | 2) dietary intake; 3) presence of 12 predefined symptoms (fever, cough, sore throat, nasal discharge, |
| 120 | sputum, headache, joint or muscle pain, severe fatigue, dyspnoea, diarrhoea, and taste or smell |
| 121 | disorder) at registration; and 4) demographic information (age, sex, height, weight, and underlying |
| 122 | disease). Outcomes defining severe disease, i.e., requiring oxygenation, mechanical ventilation, or |
| 123 | death, were collected as above. |
| 124 | |
| 125 | Characterization of SARS-CoV-2 omicron subvariants |
| 126 | Whole genome analysis was performed at the Sapporo City Institute of Public Health to |
| 127 | identify SARS-CoV-2 variants prevalent in Sapporo. Randomly collected specimens with positive |
| 128 | SARS-CoV-2 test results were analysed for approximately 50-80 cases per week, and the proportions |
| 129 | of omicron subvariants were calculated. In this study, omicron subvariant epidemic periods were |
| 130 | defined as when the percentage of the most predominant subvariants exceeded 80%. |
| 131 | |
| 132 | Statistical analysis |
| 133 | Continuous and categorical data were expressed as median (interquartile range [IQR]) and |
| 134 | proportions, respectively. A 95% confidence interval (CI) was calculated for symptom frequency, |
| 135 | odds ratio (OR), and hazard ratio. Multivariate logistic regression analyses were performed, using |
| 136 | days from symptom onset, age, sex, body mass index (BMI), underlying diseases, omicron |

| 137 | subvariants, vaccination status, and previous SARS-CoV-2 infection as explanatory variables, with |
|-----|--|
| 138 | the development of each symptom as the outcome. To estimate symptom time courses, frequencies of |
| 139 | the 12 predefined symptoms were calculated from individuals aligned by days from the first |
| 140 | symptom onset and plotted on a day 0-5 scale. Estimates of the relative rates of symptom |
| 141 | accumulation were analysed using a Cox regression model. Regarding logistic regression analysis for |
| 142 | progression to severe disease, all symptoms were incorporated in addition to the factors included in |
| 143 | the above-mentioned multivariable symptoms analysis. All statistical analyses were performed using |
| 144 | JMP® Pro Version 16.2.0 (SAS Institute Inc., Cary, NC, USA). |
| 145 | |
| 146 | Results |
| 147 | Study population |
| 148 | Data collected from the TDS and RCPP systems were analysed between April 25, 2022, and |
| 149 | September 25, 2022. The epidemic period for the omicron subvariant BA.2 spanned April 25 to June |
| 150 | 26, and that for BA.5 spanned July 18 to September 25 (Fig. 1). After individuals who met the |
| 151 | exclusion criteria were excluded (< 5.6%), a total of 157,861 symptomatic COVID-19 cases (34,336 |
| 152 | and 123,525 for the BA.2 and BA.5 groups, respectively) were analysed (Fig. 1). |
| 153 | The median age of all individuals included in the study was 33 years (range 0–104) (Table |
| 154 | 1). The most prevalent age group was the 30-year-old group, and those aged \geq 65 years accounted for |
| 155 | 9.3% of the total. Forty-eight percent were men, and the median BMI was 21.1 (IQR 18.6–24.0). The |

| 156 | proportion of patients with an underlying disease was highest for hypertension (5.6%), followed by |
|-----|--|
| 157 | chronic respiratory (3.6%) and cardiovascular diseases (1.0%). SARS-CoV-2 vaccination status was: |
| 158 | 38.0% unvaccinated, 0.7% one dose, 24.3% two doses, 33.8% three doses, and 3.2% four doses. |
| 159 | Additionally, 3.7% had a history of previous SARS-CoV-2 infection. Coughing was the most |
| 160 | prevalent symptom (62.7%), followed by sore throat (60.7%), nasal discharge (44.3%), headache |
| 161 | (42.1%), and fever (38.8%) (Fig. 2A, Table S1). A total of 142 individuals developed severe disease, |
| 162 | and four died within 30 days after onset. The risk of progression to severe disease was 0.02% for |
| 163 | individuals younger than 65 years of age and 1.01% for those at this age or over (Table 1). |
| 164 | |
| 165 | Clinical manifestations of individuals infected with omicron BA.2 or BA.5 |
| 166 | The clinical features of symptomatic individuals with BA.2 vs. BA.5 infections were also |
| 167 | compared (Table 1). The BA.2 group had a lower median age, BMI, history of cerebrovascular |
| 168 | disease, and a higher proportion of unvaccinated and ≤ 2 dose-vaccinated individuals. The BA.5 |
| 169 | group exhibited higher proportions of other comorbidities, e.g., malignancy, immunodeficiency, |
| 170 | cardiovascular disease, hypertension, and diabetes, previous SARS-CoV-2 infection, and contained |
| 171 | all individuals with a fourth vaccine dose. |
| 172 | All 12 predefined symptoms, except for nasal discharge and phlegm, were more prevalent in |
| 173 | the BA.5 vs. BA.2 populations (Fig. 2B, Table S1), findings that were replicated in the unvaccinated |
| 174 | BA.5 vs. BA.2 subgroups (Fig. S2, Table S2). Multivariate analyses of the BA.5 and BA.2 |

| 175 | population data identified associations that predicted an increased risk, for BA.5-infected populations |
|-----|---|
| 176 | of fever (adjusted OR [95% CI]: 2.18 [2.12-2.25]), decreased food intake (1.80 [1.75-1.86]), severe |
| 177 | fatigue (1.64 [1.59-1.69]), joint or muscle pain, smell or taste disorders, headache, dyspnoea, |
| 178 | diarrhoea, and sore throat, juxtaposed to a decreased risk of nasal discharge and phlegm (Fig. 2C, |
| 179 | Table S3). Logistic regression analysis demonstrated comparable odds for progression to severe |
| 180 | disease between the two subvariants (Table S4). |
| | |

181

182 Associations between vaccine status and COVID-19 symptoms

Individuals were divided into two subgroups to determine the effects of the modification of host immune status by vaccination on the prevalence of COVID-19 symptoms. The boundary between the two subgroups was set at three vaccinations, a number clinically effective for omicron variants¹⁶⁻¹⁸. The group with \geq 3 vaccinations exhibited breakthrough infections, and a lower frequency of fever, decreased food intake, severe fatigue, joint or muscle pain, and diarrhoea than the group with \leq 2 vaccinations (**Fig. 3A, Table S1**). In contrast, cough, sore throat, nasal discharge, and phlegm were more common with breakthrough infections in the \geq 3 vaccination group.

Logistic regression analysis demonstrated that individuals with breakthrough infections and ≥ 3 vaccinations had a decreased risk of systemic symptoms, including fever (0.50 [0.49–0.51]), decreased food intake (0.39 [0.37–0.40]), severe fatigue (0.59 [0.58–0.61]), joint or muscle pain, headache, diarrhoea, smell or taste disorders, and dyspnoea, as compared to individuals with ≤ 2

| 194 | vaccinations (Fig. 3B, Table S3). In contrast, the likelihood of upper airway symptoms, including |
|-----|--|
| 195 | nasal discharge (1.84 [1.80-1.89]), cough (1.49 [1.45-1.52]), sore throat (1.33 [1.29-1.36]), and |
| 196 | phlegm, were higher in individuals who received ≥ 3 vaccinations than those who received ≤ 2 |
| 197 | vaccinations. Similar analyses performed on the ≥ 3 vaccine dose group, incorporating the time |
| 198 | elapsed since the last vaccination date as a variable, revealed that longer periods from the last |
| 199 | vaccination date were associated with: 1) an increased risk of fever, headache, joint or muscle pain, |
| 200 | decreased food intake, and severe fatigue; and 2) a decreased risk of coughing, nasal discharge, sore |
| 201 | throat, and dyspnoea (Table S5). |
| 202 | The estimated temporal course of breakthrough omicron symptoms differed with |
| 203 | vaccination status for upper respiratory but not systemic symptoms (Fig. 3C, S3, Table S6). Cox |
| 204 | regression analyses, using the presence of symptoms as the occurrence of an event, revealed that the |
| 205 | appearance of coughing, sore throat, nasal discharge, and phlegm, but not systemic symptoms, were |
| 206 | significantly accelerated in the \geq 3 vs. \leq 2 vaccination groups (Table S7). |
| 207 | The study population was also divided into subgroups based on a history of previous |
| 208 | SARS-CoV-2 infection. The individuals with previous SARS-CoV-2 infection exhibited associations |
| 209 | similar to vaccination status, including a higher likelihood of upper respiratory symptoms and a |
| 210 | lower likelihood of systemic symptoms (Fig. S4, Table S3, S6, S7). |
| 211 | |

Associations between COVID-19 symptoms and clinical outcomes in elderly individuals

| 213 | The frequency of each symptom by age group was calculated (Fig. 4A, Table S8). Fever |
|-----|--|
| 214 | and decreased food intake were most frequent in individuals under 10 years of age and decreased |
| 215 | with age. Cough frequency exhibited bimodal peaks in the 20s and 70s age groups. Other symptoms |
| 216 | were most frequent in individuals in their 20s and 30s, with frequencies decreasing with increasing |
| 217 | age throughout the 70s. Consistent with these data, multivariate analysis identified advanced age (\geq |
| 218 | 65 years) as an independent factor associated with a lower likelihood of development of any |
| 219 | symptom than younger ages (Fig. 4B, Table S9). |
| 220 | Multivariate analyses identified specific COVID-19 symptoms associated with adverse |
| 221 | clinical outcomes in elderly individuals. Dyspnoea, fever, decreased food intake, and severe fatigue |
| 222 | were associated with an increased risk of severe disease (3.01 [1.84-4.91], 2.91 [1.89-4.51], 2.41 |
| 223 | [1.55-3.74], and 1.93 [1.22-3.07], respectively). The combination of these four symptoms was |
| 224 | associated with an increased risk of severe disease (adjusted OR [95% CI] for the number of |
| 225 | symptoms 1-4 with none as a reference: 2.98 [1.73-5.14], 7.46 [4.15-13.41], 14.38 [7.14-28.98], |
| 226 | and 40.72 [14.72-112.68], respectively) (Fig. 4C, Table S10). In contrast, sore throat and nasal |
| 227 | discharge were associated with a decreased risk of severe disease $(0.39 [0.24-0.63])$ and 0.48 |
| 228 | [0.28-0.82], respectively). The combination of these two upper airway symptoms was associated |
| 229 | with a decreased risk of severe disease (adjusted OR [95% CI] with no upper respiratory symptom as |
| 230 | a reference: 0.20 [0.09–0.46]) (Fig. 4C, Table S10). |

231

232 Discussion

| 233 | The registry-based self-entry COVID-19 symptom study was conducted over an interval |
|-----|--|
| 234 | when two omicron subvariants were prevalent. Collectively, individuals with omicron infections |
| 235 | exhibited more commonly upper respiratory symptoms, e.g., cough, sore throat, and nasal discharge, |
| 236 | than systemic symptoms (Fig. 2A). The clinical features of individuals with omicron breakthrough |
| 237 | infections differed from those in the early Wuhan strain-dominated pandemic period, which was |
| 238 | characterized by a higher frequency of fever, cough, dyspnoea, and fatigue and a lower frequency of |
| 239 | upper airway symptoms ¹⁹⁻²¹ . The pattern of a higher incidence of upper respiratory symptoms and a |
| 240 | lower incidence of systemic symptoms was replicated in unvaccinated individuals with omicron |
| 241 | infections (Fig. S2), suggesting that the viral strain is a variable causing difference in clinical |
| 242 | manifestations between individuals with the Wuhan strain and omicron breakthrough infection. |
| 243 | The omicron subvariants themselves also differed concerning symptom frequencies. |
| 244 | Although emerging later in the pandemic, BA.5 was associated with a higher prevalence of |
| 245 | symptoms than BA.2 (Fig. 2B). The increased BA.5 symptom prevalence may reflect greater escape |
| 246 | from humoral immunity with increased upper airway viral loads as compared to BA.2 ^{22,23} . Notably, |
| 247 | the risk of progression to severe disease did not significantly differ between BA.2 vs. BA.5 (Table |

248 **S4**).

Significant associations between vaccination status or previous COVID-19 infection and
 specific symptoms following omicron breakthrough infection were also identified. For example, a

medRxiv preprint doi: https://doi.org/10.1101/2023.02.02.23285393; this version posted February 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

251 reduced risk of systemic symptoms, including fever, fatigue, and headache, was observed in 252 individuals with omicron infections and ≥ 3 vaccinations or a history of previous infection. In 253 contrast, a strong correlation was observed between a history of ≥ 3 vaccinations or previous infection and increased upper airway symptom prevalence (Fig. 3B, S4). These contrasting 254 255post-vaccination symptom-based observations may reflect: 1) vaccine-mediated reductions in viral 256 load, reduced cytokine release into the systemic circulation, and, hence, reduced systemic symptoms²⁴⁻²⁶, and 2) vaccine-mediated amplification of local host antiviral responses to upper 257 258 respiratory tract SARS-CoV-2 infection, the consequences being increased symptom prevalence but shorter symptom duration (**Fig. 3**) 27,28 . The increased prevalence of post-breakthrough upper 259 260 respiratory symptoms after vaccinations likely accounts for the unexplained increase in total 261 symptom burden, but reduced systemic symptoms (fever and chills), recently reported in a cohort of 262 vaccinated United States Essential and Frontline workers after SARS-CoV-2 breakthrough infections²⁴. 263

We observed a decreasing frequency of COVID-19 symptoms with age (**Fig. 4B**). These findings are consistent with an earlier study showing that typical COVID-19 symptoms were less commonly reported in adult groups with advanced $age^{29,30}$. Importantly, if systemic symptoms were present in the elderly (\geq 65-year-old group), strong associations with severe disease were observed (**Fig. 4C**), consistent with reports on pre-vaccinated United States veterans³. Unexpectedly, our data suggest that upper respiratory tract symptoms are associated with a reduced risk of severe disease in

the elderly.

271 Our study had several limitations, starting with symptom data being entered directly by 272 individuals without the assistance of healthcare providers. This is a significant limitation as 273 self-reported symptoms are inherently subjective, leading to increased variability. However, these 274 are the data frequently provided in clinical encounters. Second, since symptom data were analysed 275for 12 predefined questions, COVID-19 symptoms other than the predefined items, including 276 neurological and psychological symptoms, were not evaluated. Third, the reporting of clinical 277 symptom intensity was not collected; thus, quantitative assessments of symptom intensity were not 278 performed. Fourth, asymptomatic individuals were not enrolled in the TDS or RCPP and were 279 excluded from the study. Thus, it is unknown how vaccination and previous infection may have 280 affected the presence of symptoms in the overall population. Fifth, our study was a retrospective 281 observational study and did not provide prospective information describing the duration of 282 COVID-19 symptoms. However, our system, entering symptoms singly at the time of diagnosis with data describing the onset of symptoms, juxtaposed to the large sample size, allowed us to 283 estimate the dynamics of COVID-19 symptoms. Finally, the small number of individuals with 284 severe disease may have resulted in a statistically underpowered detection of factors potentially 285 associated with severe COVID-19 outcomes. Nevertheless, the significance of the specific 286 symptoms identified as independent factors associated with severe outcomes was statistically 287 288 robust.

| 289 | In conclusion, our symptom-based description of the clinical manifestations of COVID-19 |
|-----|--|
| 290 | during the BA.2- and BA.5-dominated COVID-19 pandemic periods provides practical insights into |
| 291 | clinical features of the current COVID-19 pandemic. First, BA.5 infections were associated with |
| 292 | more prevalent symptoms than BA.2 infections in both vaccinated and unvaccinated individuals. |
| 293 | These data suggest that BA.5 emerged as a more troublesome variant than the BA.2 antecedent. |
| 294 | Second, an increased prevalence of local upper respiratory tract symptoms, but reduced systemic |
| 295 | symptom prevalence, was observed post-vaccination (or previous infection) following omicron |
| 296 | breakthrough infections. Thus, it might be appropriate to counsel individuals contemplating |
| 297 | vaccination that post-vaccination breakthrough COVID-19 infections may be associated with an |
| 298 | increased likelihood of upper airway symptoms, with offsetting benefits being a shorter symptom |
| 299 | interval and a reduced risk of severe outcomes. Third, individuals with advanced age experienced, on |
| 300 | average, fewer omicron-induced symptoms, but when present, systemic but not upper respiratory |
| 301 | symptoms heralded worsened outcomes. These observations may serve as a practical guide to utilize |
| 302 | COVID-19 symptoms to predict clinical outcomes for elderly patients with omicron infections. |

303

304 Acknowledgment

The authors thank the Public Health Office, Health and Welfare Bureau, City of Sapporo, which has long been involved in the identification of all infected populations in Sapporo since the beginning of the COVID-19 epidemic and in the management and integration of the data. Additionally, we thank

| 308 | the Sappor | o City | Institute | of Public | Health | for | providing | genomic | information | on | Sapporo's |
|-----|-------------|--------|-----------|--------------|--------|-----|-----------|---------|-------------|----|-----------|
| 309 | prevalent S | ARS-C | oV-2 muta | ant strains. | | | | | | | |
| | | | | | | | | | | | |

310

311 Ethical Approval Statement

- The research protocol was approved by the Ethics Committee of Hokkaido University Hospital (Research No. 022-0225). Analysis was performed using database in Sapporo city, with no additional risks to the patients. Therefore, the requirement for informed consent from individual participants was waived by the ethics committee. All methods were performed in accordance with the relevant guidelines and regulations of the Ethics Committee of Hokkaido University Hospital. All patient data were anonymized.
- 318

319 Author contributions

- 320 This study was designed by SN, NK, and KO. The underlying data were verified by SN, NK, MI,
- and YI, and data analyses were performed by SN, YI, and IY. SN wrote the first draft of the
- 322 manuscript, which was revised by KO, KK, MS, RCB, and KS. All authors interpreted the data,
- 323 provided a critical review and revision of the text, and approved the final version of the manuscript.

324

325 **Declaration of interests**

326 IY reports grants from the Japan Agency for Medical Research and Development (AMED), as well

| 327 | as Health, Labour and Welfare Policy Research Grants, and speaker fees from Chugai |
|-----|--|
| 328 | Pharmaceutical Co., and AstraZeneca, outside the submitted work. The other authors declare that |
| 329 | they have no conflict of interest. |
| 330 | |
| 331 | Funding |
| 332 | This project was supported in part by AMED under Grant JP223fa627005 and JP21zf0127004, the |
| 333 | National Institutes of Health, the National Institute of Diabetes and Digestive and Kidney Diseases |
| 334 | (P30 DK065988 to RCB), the Cystic Fibrosis Foundation (RDP BOUCHE15R0 to RCB; |
| 335 | BOUCHE19XX0 to RCB and KO; OKUDA20G0 to KO), and a research grant from the Cystic |
| 336 | Fibrosis Research Institute to KO. This project was also partially supported by the Rapidly Emerging |
| 337 | Antiviral Drug Development Initiative at the University of North Carolina at Chapel Hill, funded by |
| 338 | the North Carolina coronavirus state and local fiscal recovery funds program appropriated by the |
| 339 | North Carolina General Assembly, and by the project of junior scientist promotion at Hokkaido |
| 340 | University. |
| 341 | |
| 342 | References |
| 343 | 1. WHO COVID-19 Dashboard. Geneva: World Health Organization. Available online: |
| 344 | https://covid19whoint/ (last cited: [Jan. 9th, 2023] |
| 345 | 2. Terada M, Ohtsu H, Saito S, et al. Risk factors for severity on admission and the disease |

346 progression during hospitalisation in a large cohort of patients with COVID-19 in Japan. BMJ Open

347 2021; **11**(6): e047007.

348 3. Ioannou GN, Locke E, Green P, et al. Risk Factors for Hospitalization, Mechanical
349 Ventilation, or Death Among 10□131 US Veterans With SARS-CoV-2 Infection. *JAMA Netw Open*350 2020; 3(9): e2022310.

4. O'Driscoll M, Ribeiro Dos Santos G, Wang L, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* 2021; **590**(7844): 140-5.

Lacy J, Mensah A, Simmons R, et al. Protective effect of a first SARS-CoV-2 infection from
reinfection: a matched retrospective cohort study using PCR testing data in England. *Epidemiol Infect* 2022; **150**: e109.

6. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021; **373**: n1088.

7. Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1
nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in
England (VIVALDI): a prospective cohort study. *Lancet Infect Dis* 2021; 21(11): 1529-38.

Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital
admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant
dominance: a prospective observational study from the ZOE COVID Study. *Lancet* 2022; **399**(10335): 1618-24.

Bager P, Wohlfahrt J, Bhatt S, et al. Risk of hospitalisation associated with infection with
SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. *The Lancet Infect Dis* 2022; 22(7): 967-76.

10. Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread
escape from neutralizing antibody responses. *Cell* 2022; **185**(3): 467-84.e15.

11. Martinuzzi E, Boutros J, Glaichenhaus N, Marquette CH, Hofman P, Benzaquen J. Escape

- of SARS-CoV-2 Variant Omicron to Mucosal Immunity in Vaccinated Subjects. *Open Forum Infect Dis* 2022; 9(8): ofac362.
- 12. Kuhlmann C, Mayer CK, Claassen M, et al. Breakthrough infections with SARS-CoV-2
- omicron despite mRNA vaccine booster dose. *Lancet* 2022; **399**(10325): 625-6.
- 13. Alizadehsani R, Alizadeh Sani Z, Behjati M, et al. Risk factors prediction, clinical outcomes,
- and mortality in COVID-19 patients. *J Med Virol* 2021; **93**(4): 2307-20.
- Jain V, Yuan JM. Predictive symptoms and comorbidities for severe COVID-19 and
 intensive care unit admission: a systematic review and meta-analysis. *Int J Public Health* 2020;
 65(5): 533-46.
- 15. Fernández-de-Las-Peñas C, Cancela-Cilleruelo I, Rodríguez-Jiménez J, et al.
 Associated-Onset Symptoms and Post-COVID-19 Symptoms in Hospitalized COVID-19 Survivors
 Infected with Wuhan, Alpha or Delta SARS-CoV-2 Variant. *Pathogens* 2022; **11**(7).
- 16. Nemet I, Kliker L, Lustig Y, et al. Third BNT162b2 Vaccination Neutralization of
 SARS-CoV-2 Omicron Infection. *N Engl J Med* 2022; **386**(5): 492-4.
- 17. Accorsi EK, Britton A, Fleming-Dutra KE, et al. Association Between 3 Doses of mRNA
- COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta
 Variants. *JAMA* 2022; **327**(7): 639-51.
- 18. Lauring AS, Tenforde MW, Chappell JD, et al. Clinical severity of, and effectiveness of
 mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the
 United States: prospective observational study. *BMJ* 2022; **376**: e069761.
- 392 19. Komagamine J, Yabuki T. Initial symptoms of patients with coronavirus disease 2019 in
 393 Japan: A descriptive study. *J Gen Fam Med* 2021; 22(1): 61-4.
- 394 20. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China.
 395 *N Engl J Med* 2020; **382**(18): 1708-20.
- 396 21. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus Disease (COVID-19):

397 Comprehensive Review of Clinical Presentation. *Front Public Health* 2020; **8**: 582932.

- 398 22. Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2
- 399 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. *Cell* 2022; **185**(14): 2422-33.e13.
- 400 23. Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by
- 401 Omicron infection. *Nature* 2022; **608**(7923): 593-602.
- 402 24. Network TH-R. Association of mRNA Vaccination With Clinical and Virologic Features of
- 403 COVID-19 Among US Essential and Frontline Workers. JAMA 2022; **328**(15): 1523-33.
- 404 25. Fan Q, Shi J, Yang Y, et al. Clinical characteristics and immune profile alterations in
- vaccinated individuals with breakthrough Delta SARS-CoV-2 infections. *Nat Commun* 2022; **13**(1):
 3979.
- 407 26. Mucosal IgA against SARS-CoV-2 Omicron Infection. *N Engl J Med* 2022; **387**(21): e55.

408 27. Ssemaganda A, Nguyen HM, Nuhu F, et al. Expansion of cytotoxic tissue-resident CD8+ T

409 cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19

- 410 vaccination. *Nat Commun* 2022; **13**(1): 3357.
- 41128.Lim JME, Tan AT, Le Bert N, Hang SK, Low JGH, Bertoletti A. SARS-CoV-2 breakthrough

infection in vaccinees induces virus-specific nasal-resident CD8+ and CD4+ T cells of broad
specificity. *J Exp Med* 2022; **219**(10).

- 414 29. Gómez-Belda AB, Fernández-Garcés M, Mateo-Sanchis E, et al. COVID-19 in older adults:
- 415 What are the differences with younger patients? *Geriatr Gerontol Int* 2021; **21**(1): 60-5.
- 416 30. Trevisan C, Noale M, Prinelli F, et al. Age-Related Changes in Clinical Presentation of
- 417 Covid-19: the EPICOVID19 Web-Based Survey. *Eur J Intern Med* 2021; **86**: 41-7.

418 Figure legends

| 419 | Figure 1. Schematic representations of the study period and eligibility determination. The bars |
|-----|---|
| 420 | indicate the number of persons with new infections per day in Sapporo. The stacked area graph |
| 421 | shows the detection rate of mutant strains in Sapporo. The BA.2 period was defined as when the |
| 422 | detection rate of omicron subvariant BA.2 exceeded 80%, and the BA.5 period was defined as when |
| 423 | the detection rate of BA.5 exceeded 80% and until the end of notifiable disease surveillance in |
| 424 | Sapporo. |
| 425 | |
| 426 | Figure 2. Association of COVID-19 symptoms with the omicron subvariants BA.2 and BA.5. |
| 427 | A. Frequency of COVID-19 symptoms in the total study population. B. Frequency of COVID-19 |
| 428 | symptoms in individuals with BA.2 and BA.5 infections. Error bars indicate 95% confidence |
| 429 | intervals (CIs). C. Associations between omicron subvariants and symptom likelihood. Multivariate |
| 430 | analysis used each symptom as an outcome and mutant strain, age, body mass index, underlying |
| 431 | disease, vaccination history, and history of spontaneous infection as explanatory variables. The type |
| 432 | of omicron subvariant (BA.5 or not) and the adjusted odds ratio (OR) for each symptom are arranged |
| 433 | from highest to lowest. Points indicate ORs, and bars indicate 95% CIs. The detailed results of the |
| 434 | multivariate analysis are presented in Table S3. |
| 435 | |

436 Figure 3. Associations between vaccine status and COVID-19 symptoms.

| 437 | A. Symptom frequency is shown in two groups divided by vaccination status. B. Associations |
|-----|---|
| 438 | between vaccination and symptom likelihood. Multivariate analysis used each symptom as an |
| 439 | outcome and mutant strain, age, body mass index, underlying disease, vaccination history, and |
| 440 | history of spontaneous infection as explanatory variables. The detailed results of the multivariate |
| 441 | analysis are presented in Table S3. Three or more vaccinations and the adjusted odds ratio (OR) for |
| 442 | each symptom are arranged from highest to lowest. Points indicate ORs, and bars indicate 95% |
| 443 | confidence intervals (CIs). C. Symptom frequency by day since symptom onset in the two groups |
| 444 | divided by vaccination status. Error bars indicate 95% CIs. |
| 445 | |
| 446 | Figure 4. Associations of COVID-19 symptoms with age and progression to severe disease. |
| 447 | A. Frequency of COVID-19 symptoms according to age. The shade colour of the cells is linked to |
| 448 | the high and low percentage values. B. Associations between age and symptom likelihood. |
| 449 | Multivariate analysis used each symptom as an outcome and mutant strain, age (elderly or |
| 450 | non-elderly), body mass index, underlying disease, vaccination history, and history of spontaneous |

infection as explanatory variables. Elderly individuals (age \geq 65 years) and the adjusted odds ratio (OR) for each symptom are arranged from highest to lowest. **C.** OR for COVID-19 symptoms and progression to severe disease. Multivariate analysis was performed using progression to severe disease as an outcome and mutant strain, age, body mass index, underlying disease, vaccination history, history of previous infection, and all symptoms as explanatory variables. Symptoms are

- 456 sorted in descending order of OR for progression to severe disease. Points indicate ORs, and bars
- 457 indicate 95% confidence intervals. The detailed results of the multivariate analysis are presented in
- 458 **Table S4**.

459


460 **Table 1. Clinical characteristics of the study population.**


| | Total (N=157,861) | BA.2 (n=34,336) | BA.5 (n=123,525) |
|--|-------------------|------------------|------------------|
| Median age (range)-yr | 33 (0-104) | 28 (0-102) | 34 (0-104) |
| Age * – no. (%) | | | |
| < 10 | 23,219 (14.7) | 6,427 (18.8) | 16,792 (13.6) |
| 10s | 21,165 (13.4) | 6,012 (17.6) | 15,153 (12.3) |
| 20s | 26,259 (16.7) | 5,667 (16.6) | 20,592 (16.7) |
| 30s | 27,665 (17.6) | 6,093 (17.8) | 21,572 (17.5) |
| 40s | 26,536 (16.8) | 5,465 (16) | 21,071 (17.1) |
| 50s | 16,629 (10.6) | 2,434 (7.1) | 14,195 (11.5) |
| 60s | 8,881 (5.6) | 1,156 (3.4) | 7,725 (6·3) |
| 70s | 4,839 (3.1) | 647 (1.9) | 4,192 (3.4) |
| ≥ 80 | 2,359 (1.5) | 310 (0.9) | 2,049 (1.7) |
| Elderly (Age \geq 65) – no. (%) | 10,874 (9.3) | 1,441 (9.6) | 9,433 (7.6) |
| Sex ** – no. (%) | | | |
| Male | 75,281 (47.7) | 16,292 (47.5) | 58,989 (47.8) |
| Female | 82,468 (52.3) | 18,012 (52.5) | 64,456 (52.2) |
| Median BMI *** (IQR) | 21.1 (18.6-24.0) | 20.7 (18.1-23.5) | 21.2 (18.7-24.1) |
| Obesity $(BMI \ge 30) - no. (\%)$ | 6,729 (4.3) | 1,241 (3.6) | 5,488 (4.4) |
| Comorbidities – no. (%) | | | |
| Malignancy | 1,284 (0.8) | 188 (0.5) | 1,096 (0.9) |
| Immunocompromised | 291 (0.2) | 44 (0.1) | 247 (0.2) |
| Chronic respiratory diseases | 5,652 (3.6) | 1,186 (3.5) | 4,466 (3.6) |
| Chronic kidney diseases | 88 (0.1) | 15 (0.1) | 73 (0.0) |
| Cardiovascular diseases | 1,620 (1.0) | 229 (0.7) | 1,391 (1.1) |
| Cerebrovascular diseases | 102 (0.1) | 22 (0.1) | 80 (0.1) |
| Hypertension | 8,781 (5.6) | 1,270 (3.7) | 7,511 (6.1) |
| Diabetes | 3,740 (2.4) | 550 (1.6) | 3,190 (2.6) |
| SARS-CoV-2 vaccination – no. (%) | | | |
| Unvaccinated | 60,033 (38.0) | 15,339 (44.7) | 44,694 (36·2) |
| One dose | 1,052 (0.7) | 341 (1.0) | 711 (0.6) |
| Two doses | 38,304 (24.3) | 11,232 (32.7) | 27,072 (21.9) |
| Three doses | 53,389 (33.8) | 7,424 (21.6) | 45,965 (37.2) |
| Four doses | 5,083 (3.2) | 0 (0.0) | 5,083 (4.1) |
| Previous SARS-CoV-2 infection – no. (%) | 5,767 (3.7) | 732 (2.1) | 5,035 (4.1) |
| Progression to severe disease – no. (%) | 142 (0.1) | 19 (0.1) | 123 (0.1) |
| Among the elderly (Age ≥ 65 years) | 110 (1.01) | 12 (0.83) | 98 (1·04) |

| Among individuals aged < 65 years | 31 (0.02) | 7 (0.02) | 24 (0.02) |
|-----------------------------------|-----------|----------|-----------|
| Death within 30 days – no. | 4 | 2 | 2 |

461 *N=157,552, **N=157,749, ***N=157,781.


462 BMI, body mass index; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.






С


BA.5 (compared with BA.2)



Odds ratio



В




| A | <10 (n=23219) | 10s (n=21165) | 20s (n=26259) | 30s (n=27665) | 40s (n=26536) | 50s (n=16629) | 60s (n=8881) | 70s (n=4839) | 80 or over (n=2359) |
|--|--|--|---|-------------------------|----------------------|----------------------|-----------------|------------------------|---------------------------|
| Fever | 54.3% | 48.2% | 41.2% | 38.3% | 34.1% | 29.5% | 20.6% | 14.5% | 16.5% |
| Cough | 46.7% | 59.5% | 69.6% | 65.0% | 63.8% | 67.5% | 69.5% | 69.5% | 61.6% |
| Sore throat | 22.0% | 65.3% | 73.4% | 69.1% | 67.7% | 67.6% | 63.5% | 54.6% | 35.1% |
| Nasal discharge | 36.8% | 42.6% | 50.6% | 48.1% | 44.6% | 44.5% | 43.8% | 38.1% | 30.8% |
| Phlegm | 15.7% | 34.1% | 47.6% | 43.0% | 39.3% | 36.2% | 33.4% | 31.2% | 28.1% |
| Headache | 21.2% | 44.4% | 50.2% | 51.9% | 48.8% | 44.6% | 32.0% | 20.5% | 10.1% |
| Joint or muscle pain | 8.2% | 21.0% | 36.3% | 40.3% | 38.0% | 33.8% | 24.1% | 16.1% | 8.4% |
| Decreased food intake | 34.7% | 35.1% | 30.4% | 26.6% | 25.3% | 24.5% | 16.8% | 15.0% | 18.4% |
| Severe fatigue | 15.0% | 25.5% | 33.5% | 34.4% | 29.8% | 25.8% | 18.3% | 15.6% | 17.4% |
| medRxiv preprint doi: https://doi.org/10.1101/2023.02.02.23285393; this version of the section o | 7, 2 02 3. % e co cense to display license . | pp yli@i t polog r fo / the preprint in | or DiS pr op 4/4 perpetuity. | 18.3% | 16.4% | 16.7% | 13.4% | 11.3% | 14.0% |
| Diarrhea | 8.3% | 7.7% | 8.8% | 8.9% | 8.2% | 7.1% | 5.0% | 3.6% | 3.3% |
| Smell or taste disorder | 1.1% | 3.2% | 5.0% | 4.8% | 4.0% | 4.3% | 3.8% | 3.0% | 2.0% |

В

С





| Т | 0 | t | а | |
|---|---|---|---|---|
| | ~ | | 9 | • |

| (N=157552) |
|------------|
| 38.8% |
| 62.7% |
| 60.7% |
| 44.3% |
| 36.1% |
| 42.1% |
| 29.1% |
| 28.1% |
| 26.8% |
| 15.1% |
| 7.8% |
| 3.7% |

Progression to severe disease